All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How can Day 100 transcriptomics help to predict development of chronic GvHD?
Bookmark this article
During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Ben Watkins, Emory University, Atlanta, US. We asked, How can Day 100 transcriptomics help to predict development of chronic GvHD?
How can Day 100 transcriptomics help to predict development of chronic GvHD?
Watkins discusses a model analyzing CD4 T-cell transcriptomics at Day 100 in patients who develop de novo chronic GvHD versus patients displaying operational immune tolerance. Day 100 represented the optimal timepoint to study, as this is often the inflection point between acute and chronic GvHD.
More about...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox